Peripheral neuropathy in non-Hodgkin's lymphoma patients receiving vincristine with and without aprepitant/fosaprepitant

JK Edwards, JB Bossaer, PO Lewis… - Journal of Oncology …, 2020 - journals.sagepub.com
Background Peripheral neuropathy is a common treatment-related adverse effect associated
with vincristine. Vincristine is a major CYP3A4 substrate and is often administered alongside …
被引用次数：13 相关文章 所有 5 个版本
[HTML] nih.gov

[HTML][HTML] Risk factors for early-onset peripheral neuropathy caused by vincristine in patients with a first administration of R-CHOP or R-CHOP-like chemotherapy

N Okada, T Hanafusa, T Sakurada… - Journal of clinical …, 2014 - ncbi.nlm.nih.gov
Background Peripheral neuropathy is a well-known side effect of vincristine (VCR), a
microtubule inhibitor used for R-CHOP or R-CHOP-like (namely R-CVP and R-THP-COP) …
被引用次数：32 相关文章 所有 9 个版本
[PDF] mdpi.com

Vincristine-induced neuropathy in patients diagnosed with solid and hematological malignancies: the role of dose rounding

AM Alwhaibi, AA Alshamrani, MA Alenazi… - Journal of Clinical …, 2023 - mdpi.com
Background: Vincristine is a vital constituent of chemotherapeutic regimens. Vincristine-
induced neuropathy is a challenging adverse effect that impacts quality of life and treatment …
被引用次数：3 相关文章 所有 7 个版本
[PDF] springer.com

Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review

ML Madsen, H Due, N Ejskjær, P Jensen… - Cancer chemotherapy …, 2019 - Springer
Purpose Vincristine is widely used as anticancer therapy for a variety of hematological
malignancies. The treatment is limited by progressive vincristine-induced neuropathy …
被引用次数：105 相关文章 所有 11 个版本
[PDF] springer.com

Characterising vincristine-induced peripheral neuropathy in adults: symptom development and long-term persistent outcomes

T Li, T Trinh, A Bosco, MC Kiernan, D Goldstein… - Supportive Care in …, 2024 - Springer
Background Decades following the introduction of vincristine as treatment for
haematological malignancies, vincristine-induced peripheral neuropathy (VIPN) remains a …
被引用次数：1 相关文章 所有 5 个版本
[HTML] nih.gov

[HTML][HTML] Vincristine-induced peripheral neuropathy in pediatric cancer patients

E Mora, EML Smith, C Donohoe… - American journal of …, 2016 - ncbi.nlm.nih.gov
Vincristine is a chemotherapeutic agent that is a component of many combination regimens
for a variety of malignancies, including several common pediatric tumors. Vincristine …
被引用次数：186 相关文章 所有 4 个版本
[HTML] nih.gov

[HTML][HTML] Co-Morbidity Consult: Chemotherapy-Induced Peripheral Neuropathy

E Tzatha, LM DeAngelis - Oncology (Williston Park, NY), 2016 - ncbi.nlm.nih.gov
Chemotherapy-induced peripheral neuropathy (CINP) is a common treatment-related side
effect of several widely used drugs such as platinum analogs, antitubulins (taxanes, vinca …
被引用次数：21 相关文章 所有 4 个版本
[HTML] nih.gov

Prevention of chemotherapy-induced peripheral neuropathy: a review of recent findings

EY Ibrahim, BE Ehrlich - Critical reviews in oncology/hematology, 2020 - Elsevier
Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse effect of chemotherapy
that is frequently experienced by patients receiving treatment for cancer. CIPN is caused by …
被引用次数：128 相关文章 所有 5 个版本

Chemotherapy-induced peripheral neuropathy

E Noguchi, Y Maeda - Gan to Kagaku ryoho. Cancer & …, 2011 - europepmc.org
Chemotherapy-induced peripheral neuropathy (CIPN) is one of chemotherapy's common
and disabling adverse effects. It may be caused by many chemotherapeutic agents including …
被引用次数：4 相关文章 所有 2 个版本
[HTML] nih.gov

Updates in the treatment of chemotherapy-induced peripheral neuropathy

JN Mezzanotte, M Grimm, NV Shinde, T Nolan… - … treatment options in …, 2022 - Springer
Opinion statement Chemotherapy-induced peripheral neuropathy (CIPN) is a common
toxicity associated with treatment with platinum-based agents, taxanes, vinca alkaloids, and …
被引用次数：35 相关文章 所有 5 个版本